Lipid management in patients with high and very high cardiovascular risk: data from routine clinical practice in europe (SANTORINI study)
Estimating the potential impact of LDL-C lowering through siRNA therapies on population health: a simulation study
Efficacy and safety of the oral PCSK9 macrocyclic peptide inhibitor MK-0616: a phase 2b randomized controlled trial
Elevated plasma adiponectin in risk of heart failure, atrial fibrillation, aortic valve stenosis, and myocardial infarction: observational and mendelian randomization studies
Lomitapide for the treatment of paediatric homozygous familial hypercholesterolaemia patients – Results from the efficacy phase of the APH-19 study
Randomized, open-label, cross-over, phase-3 study to evaluate efficacy and safety of LIB003 compared with evolocumab in homozygous familial hypercholesterolaemia patients on stable lipid-lowering therapy (LIBerate-HoFH)
Diagnosis of familial hypercholesterolemia in a large cohort of italian genotyped hypercholesterolemic patients
Impact of bempedoic acid on cardiovascular events in high risk patients with statin intolerance: the clear outcomes study
Variants in LPA are associated with mutation-negative familial hypercholesterolaemia: genome wide association study in the 100,000 genomes project
